Systematic Review of Urinary Biomarkers for the Detection of Renal Cell Carcinoma - Top-Institutions - MDSpire

Systematic Review of Urinary Biomarkers for the Detection of Renal Cell Carcinoma

  • By

  • Jaycey F. Kelly

  • Iryna V. Samarska

  • Bram Ramaekers

  • Tom Marcelissen

  • Joep G. van Roermund

  • Maureen J. B. Aarts

  • Thomas Kerkhofs

  • Tom Hermans

  • Frits van Osch

  • Tim de Meyer

  • Leo J. Schouten

  • Kim M. Smits

  • October 30, 2025

  • 0 min

Share

Top Institutions in Urology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Urologic Oncology
    • Molecular Diagnostics
    • Cancer Biomarkers

  • #2

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Urology
    • Oncology
    • Molecular Pathology

  • #3

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, MD

    Key Differentiators

    • Urologic Oncology
    • Cancer Genomics
    • Biomarker Development

  • #4

    University of California, San Francisco (UCSF)
    University of California, San Francisco (UCSF)

    San Francisco, CA

    Key Differentiators

    • Urology
    • Cancer Biomarkers
    • Translational Medicine

  • #5

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Oncology
    • Molecular Diagnostics
    • Biomarker Research

Original Source(s)

Systematic Review of Urinary Biomarkers for the Detection of Renal Cell Carcinoma

  • by Jaycey F. Kelly, Iryna V. Samarska, Bram Ramaekers, Tom Marcelissen, Joep G. van Roermund, Maureen J. B. Aarts, Thomas Kerkhofs, Tom Hermans, Frits van Osch, Tim de Meyer, Leo J. Schouten, Kim M. Smits

  • October 30, 2025

Related Content

Update of the MSKCC nomogram for metastatic progression and its role in active surveillance: the Italian TPCP cohort

From molecular networks to translational intervention: current progress in the mechanisms of gemcitabine resistance in bladder cancer

International metastatic renal cell carcinoma database consortium classification and regression tree analysis to characterize objective response rates to first line in metastatic renal cell carcinoma